Inventiva
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
50 Rue De Dijon, Daix, Bourgogne-Franche...Phone Number
+33 380447500Website
www.inventivapharma.comRevenue
<$5 MillionStock Symbol
IVAIndustry
About Inventiva
Inventiva Org Chart
Is Inventiva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Inventiva had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Inventiva is spiking on competitors!
Earning: See what the market has to say on Inventiva recently announced quarterly report
Product Launch: Get notified when Inventiva launches new products
Check if Inventiva has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Inventiva, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Inventiva
Funding: Get notified immidiatlly once Inventiva has new funding data
Recommended Actions
Reach out to Masked Content who joined Inventiva as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Inventiva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inventiva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inventiva.
Inventiva financials insights
Gather financial insights about Inventiva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Other Financing Round
$16.4M
Stock Offering
$107.7M
Share Placement
$36.7M
Private Equity
$99.6M
Debt
$131M
Debt
$151.2M
Inventiva Tech Stack
A closer look at the technologies used by Inventiva
Most Recent Scoops
Inventiva News & Media
Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting.Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside
Inventiva S.A. (NASDAQ:IVA) is one of the 10 best stocks under $10 offering more than 50% upside. As of the June 24 close, Inventiva S.A. (NASDAQ:IVA) had a strongly bullish consensus sentiment. The stock received Buy ratings from all 9 analysts who provided coverage. Based on a 1-year median price target of $15.75, it currently […]Claret Capital Partners participates in €130m financing for Inventiva
Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inventiva
Inventiva is a clinical-stage biopharmaceutical company headquartered in France, specializing in the development of oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as fibrosis, lysosomal storage disorders, and oncology, aiming to advance innovative treatments that improve patient outcom... Read More

